[{"address1": "200-3650 Gilmore Way", "city": "Burnaby", "state": "BC", "zip": "V5G 4W8", "country": "Canada", "phone": "604 484 3300", "fax": "604 484 3450", "website": "https://www.xenon-pharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.", "fullTimeEmployees": 316, "companyOfficers": [{"maxAge": 1, "name": "Mr. Ian C. Mortimer C.M.A., CPA, M.B.A.", "age": 48, "title": "President, CEO & Director", "yearBorn": 1976, "fiscalYear": 2024, "totalPay": 1184288, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sherry  Aulin C.A., CPA", "age": 41, "title": "Chief Financial Officer", "yearBorn": 1983, "fiscalYear": 2024, "totalPay": 742650, "exercisedValue": 770996, "unexercisedValue": 3587776}, {"maxAge": 1, "name": "Ms. Andrea  DiFabio J.D.", "age": 56, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1968, "fiscalYear": 2024, "totalPay": 682252, "exercisedValue": 0, "unexercisedValue": 436894}, {"maxAge": 1, "name": "Dr. Christopher John Kenney M.D.", "age": 53, "title": "Chief Medical Officer", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 774702, "exercisedValue": 0, "unexercisedValue": 4053263}, {"maxAge": 1, "name": "Dr. Matthew D. Ronsheim Ph.D.", "age": 52, "title": "Chief Operating Officer", "yearBorn": 1972, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Shelley  McClCoskey B.A.", "age": 64, "title": "Executive Vice President of Human Resources", "yearBorn": 1960, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Robin P. Sherrington Ph.D.", "age": 63, "title": "Executive Vice President of Strategy & Innovation", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 587028, "exercisedValue": 0, "unexercisedValue": 9907717}, {"maxAge": 1, "name": "Dr. James R. Empfield Ph.D.", "age": 63, "title": "Executive Vice President of Drug Discovery", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 323428, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 30.49, "open": 30.19, "dayLow": 29.38, "dayHigh": 30.6, "regularMarketPreviousClose": 30.49, "regularMarketOpen": 30.19, "regularMarketDayLow": 29.38, "regularMarketDayHigh": 30.6, "payoutRatio": 0.0, "beta": 1.216, "forwardPE": -8.356742, "volume": 764918, "regularMarketVolume": 764918, "averageVolume": 903392, "averageVolume10days": 1654680, "averageDailyVolume10Day": 1654680, "bid": 21.82, "ask": 37.74, "bidSize": 2, "askSize": 2, "marketCap": 2282824704, "fiftyTwoWeekLow": 26.74, "fiftyTwoWeekHigh": 46.0, "priceToSalesTrailing12Months": 304.37662, "fiftyDayAverage": 33.8426, "twoHundredDayAverage": 38.500423, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 1741870592, "profitMargins": 0.0, "floatShares": 70881895, "sharesOutstanding": 76733600, "sharesShort": 3584868, "sharesShortPriorMonth": 3947500, "sharesShortPreviousMonthDate": 1743379200, "dateShortInterest": 1745971200, "sharesPercentSharesOut": 0.0468, "heldPercentInsiders": 0.00263, "heldPercentInstitutions": 1.03741, "shortRatio": 3.78, "shortPercentOfFloat": 0.052199997, "impliedSharesOutstanding": 76733600, "bookValue": 9.192, "priceToBook": 3.2365098, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -251446000, "trailingEps": -3.22, "forwardEps": -3.56, "enterpriseToRevenue": 232.249, "enterpriseToEbitda": -5.999, "52WeekChange": -0.22947425, "SandP52WeekChange": 0.09362543, "quoteType": "EQUITY", "currentPrice": 29.75, "targetHighPrice": 65.0, "targetLowPrice": 42.0, "targetMeanPrice": 55.12167, "targetMedianPrice": 55.0, "recommendationMean": 1.26316, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 18, "totalCash": 549628992, "totalCashPerShare": 7.163, "ebitda": -290361984, "totalDebt": 8675000, "quickRatio": 17.43, "currentRatio": 17.656, "totalRevenue": 7500000, "debtToEquity": 1.232, "revenuePerShare": 0.096, "returnOnAssets": -0.22032, "returnOnEquity": -0.31596002, "grossProfits": -219844000, "freeCashflow": -128485872, "operatingCashflow": -196854000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -9.6984005, "financialCurrency": "USD", "symbol": "XENE", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "cryptoTradeable": false, "marketState": "CLOSED", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1415197800000, "postMarketChangePercent": 4.16807, "postMarketPrice": 30.99, "postMarketChange": 1.24, "regularMarketChange": -0.7399998, "regularMarketDayRange": "29.38 - 30.6", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 903392, "fiftyTwoWeekLowChange": 3.0100002, "fiftyTwoWeekLowChangePercent": 0.11256546, "fiftyTwoWeekRange": "26.74 - 46.0", "fiftyTwoWeekHighChange": -16.25, "fiftyTwoWeekHighChangePercent": -0.35326087, "shortName": "Xenon Pharmaceuticals Inc.", "longName": "Xenon Pharmaceuticals Inc.", "fiftyTwoWeekChangePercent": -22.947424, "earningsTimestamp": 1747080060, "earningsTimestampStart": 1754510400, "earningsTimestampEnd": 1754942400, "earningsCallTimestampStart": 1747081800, "earningsCallTimestampEnd": 1747081800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -3.22, "epsForward": -3.56, "epsCurrentYear": -4.0302, "priceEpsCurrentYear": -7.3817677, "fiftyDayAverageChange": -4.092602, "fiftyDayAverageChangePercent": -0.12093047, "twoHundredDayAverageChange": -8.750423, "twoHundredDayAverageChangePercent": -0.22728123, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.3 - Strong Buy", "regularMarketChangePercent": -2.4270246, "regularMarketPrice": 29.75, "corporateActions": [], "postMarketTime": 1748036134, "regularMarketTime": 1748030400, "exchange": "NGM", "messageBoardId": "finmb_565718", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "displayName": "Xenon Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2025-05-24"}]